Business
Axovant update on 1st cohort of Sunrise-PD trial
Axovant update on 1st cohort of Sunrise-PD trial.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 4151B Oxford Biomedica PLC 06 June 2019 \n\n \nOxford Biomedica notes Axovant's six-month update from first cohort of Sunrise-PD Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson's disease\n \n \nOxford, UK - 6 June 2019: Oxford Biomedica plc (LSE: OXB), a leading gene and cell therapy group, notes Axovant's six-month update from first cohort of the SUNRISE-PD Phase 2 trial of AXO-Lenti-PD gene therapy in Parkinson's disease.\n \nAxovant reported six-month follow-up data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson's disease. AXO-Lenti-PD was observed to be generally well tolerated, with no serious adverse events related to the product or the procedure and patients showed continued improvement from baseline across multiple measurements.\n \nThe first patient in the second cohort of the SUNRISE-PD clinical study was dosed in April 2019 and Axovant expects initial three-month data in the fourth quarter of 2019.\n \nTo view the full announcement from Axovant, please follow this link.\n \n \n\n\n\nEnquiries:\n\n\n \n\n\n\n\n \nOxford Biomedica plc\n \nJohn Dawson, Chief Executive Officer\nStuart Paynter, Chief Financial Officer\nCatherine Isted, Head of Corporate Development & IR\nSarah MacLeod, Head of Communications\n \n\n\n \n \n \nT: +44 (0)1865 783 000\nT: +44 (0)1865 783 000\nT: +44 (0)1865 954 161 / E: [email protected]\nT: +44 (0)7747 602 739 / E: [email protected]\n\n\n\n\nConsilium Strategic Communications\n \nMary-Jane Elliott/Matthew Neal\n\n\n \n \nT: +44 (0)20 3709 5700\n\n\n\n \n \nAbout Oxford Biomedica\n \nOxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the \"Group\") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partners...